Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan L Wright

Showing results (161-170 of 204) with videos related to

Pageof 21
Sort By:
American Journal of Nuclear Medicine and Molecular Imaging|January 22, 2026
Results from a prospective registry of <sup>18</sup>F-Fluciclovine PET/CT use in prostate cancer management: a cautionary lesson for implementation of PSMA PETSteven Blinka, Risa L Wong, Sarah K Holt, et al.
Advances in Radiation Oncology|April 7, 2022
A Prospective Study of a Resorbable Intravesical Fiducial Marker for Bladder Cancer Radiation TherapyMatthew D Greer, Stephanie K Schaub, Stephen R Bowen, et al.
Bladder Cancer (Amsterdam, Netherlands)|June 10, 2021
Plasmacytoid urothelial carcinoma: response to chemotherapy and oncologic outcomesLeonidas N Diamantopoulos, Ali Raza Khaki, Petros Grivas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2017
Association of Tissue Abiraterone Levels and <i>SLCO</i> Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate CancerElahe A Mostaghel, Eunpi Cho, Ailin Zhang, et al.
The American Journal of Managed Care|January 17, 2018
Improving risk stratification among veterans diagnosed with prostate cancer: impact of the 17-gene prostate score assayJulie A Lynch, Megan P Rothney, Raoul R Salup, et al.
Clinical Genitourinary Cancer|January 29, 2023
A Phase 1/2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Muscle-Invasive Bladder CancerDimitrios Makrakis, Jonathan L Wright, Martine P Roudier, et al.
JCI Insight|May 31, 2019
Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsyBrian R Winters, Navonil De Sarkar, Sonali Arora, et al.
Cancer Research|December 2, 2021
Prostate Cancer Risk Stratification via Nondestructive 3D Pathology with Deep Learning-Assisted Gland AnalysisWeisi Xie, Nicholas P Reder, Can Koyuncu, et al.
European Urology|March 12, 2023
Corrigendum to "Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer" [Eur Urol 2023;83:313-17]Alberto Gil-Jimenez, Jeroen van Dorp, Alberto Contreras-Sanz, et al.
European Urology|August 14, 2022
Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder CancerAlberto Gil-Jimenez, Jeroen van Dorp, Alberto Contreras-Sanz, et al.
Pageof 21

Showing results (161-170 of 204) with videos related to

Sort By:
Pageof 21
American Journal of Nuclear Medicine and Molecular Imaging|January 22, 2026
Results from a prospective registry of <sup>18</sup>F-Fluciclovine PET/CT use in prostate cancer management: a cautionary lesson for implementation of PSMA PETSteven Blinka, Risa L Wong, Sarah K Holt, et al.
Advances in Radiation Oncology|April 7, 2022
A Prospective Study of a Resorbable Intravesical Fiducial Marker for Bladder Cancer Radiation TherapyMatthew D Greer, Stephanie K Schaub, Stephen R Bowen, et al.
Bladder Cancer (Amsterdam, Netherlands)|June 10, 2021
Plasmacytoid urothelial carcinoma: response to chemotherapy and oncologic outcomesLeonidas N Diamantopoulos, Ali Raza Khaki, Petros Grivas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2017
Association of Tissue Abiraterone Levels and <i>SLCO</i> Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate CancerElahe A Mostaghel, Eunpi Cho, Ailin Zhang, et al.
The American Journal of Managed Care|January 17, 2018
Improving risk stratification among veterans diagnosed with prostate cancer: impact of the 17-gene prostate score assayJulie A Lynch, Megan P Rothney, Raoul R Salup, et al.
Clinical Genitourinary Cancer|January 29, 2023
A Phase 1/2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Muscle-Invasive Bladder CancerDimitrios Makrakis, Jonathan L Wright, Martine P Roudier, et al.
JCI Insight|May 31, 2019
Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsyBrian R Winters, Navonil De Sarkar, Sonali Arora, et al.
Cancer Research|December 2, 2021
Prostate Cancer Risk Stratification via Nondestructive 3D Pathology with Deep Learning-Assisted Gland AnalysisWeisi Xie, Nicholas P Reder, Can Koyuncu, et al.
European Urology|March 12, 2023
Corrigendum to "Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer" [Eur Urol 2023;83:313-17]Alberto Gil-Jimenez, Jeroen van Dorp, Alberto Contreras-Sanz, et al.
European Urology|August 14, 2022
Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder CancerAlberto Gil-Jimenez, Jeroen van Dorp, Alberto Contreras-Sanz, et al.
Pageof 21